TY - JOUR
T1 - An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis
T2 - results from 19 countries
AU - Rollefstad, Silvia
AU - Ikdahl, Eirik
AU - Wibetoe, Grunde
AU - Sexton, Joe
AU - Crowson, Cynthia S.
AU - van Riel, Piet
AU - Kitas, George D.
AU - Graham, Ian
AU - Dahlqvist, Solbritt Rantapää
AU - Karpouzas, George
AU - Myasoedova, Elena
AU - Gonzalez-Gay, Miguel A.
AU - Sfikakis, Petros P.
AU - Tektonidou, Maria G.
AU - Lazarini, Argyro
AU - Vassilopoulos, Dimitrios
AU - Kuriya, Bindee
AU - Hitchon, Carol A.
AU - Stoenoiu, Maria Simona
AU - Durez, Patrick
AU - Pascual-Ramos, Virginia
AU - Galarza-Delgado, Dionicio Angel
AU - Faggiano, Pompilio
AU - Misra, Durga Prasanna
AU - Borg, Andrew
AU - Mu, Rong
AU - Mirrakhimov, Erkin M.
AU - Gheta, Diane
AU - Myasoedova, Svetlana
AU - Krougly, Lev
AU - Popkova, Tatiana
AU - Tuchyňová, Alena
AU - Tomcik, Michal
AU - Vrablik, Michal
AU - Lastuvka, Jiri
AU - Horák, Pavel
AU - Medková, Helena
AU - Semb, Anne Grete
N1 - Publisher Copyright:
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Aims To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). Methods and results The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014-19. The treatment goal for BP was <140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. Conclusion We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.
AB - Aims To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). Methods and results The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014-19. The treatment goal for BP was <140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. Conclusion We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.
KW - Audit
KW - Blood pressure
KW - Lipids
KW - Prevention
KW - Rheumatoid arthritis
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=85117160897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117160897&partnerID=8YFLogxK
U2 - 10.1093/ehjcvp/pvab052
DO - 10.1093/ehjcvp/pvab052
M3 - Article
C2 - 34232315
AN - SCOPUS:85117160897
SN - 2055-6837
VL - 8
SP - 539
EP - 548
JO - European Heart Journal - Cardiovascular Pharmacotherapy
JF - European Heart Journal - Cardiovascular Pharmacotherapy
IS - 6
ER -